{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:35:28Z","timestamp":1791596128530,"version":"4.3.4"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejmech.2019.06.092","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T12:43:07Z","timestamp":1562157787000},"page":"791-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":263,"special_numbering":"C","title":["Boron in drug design: Recent advances in the development of new therapeutic agents"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5466","authenticated-orcid":false,"given":"Guilherme Felipe Santos","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7997-1843","authenticated-orcid":false,"given":"William Alexander","family":"Denny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-2829","authenticated-orcid":false,"given":"Jean Leandro","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.06.092_bib1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/fmc.09.71","article-title":"Therapeutic potential of boron-containing compounds","volume":"1","author":"Baker","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/13543776.2018.1473379","article-title":"Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018)","volume":"28","author":"Nocentini","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2019.06.092_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1039\/C7MD00552K","article-title":"Synthesis of biologically active boron-containing compounds","volume":"9","author":"Yang","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2019.06.092_bib4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/tcr.201402100","article-title":"Boron-based drug design","volume":"15","author":"Ban","year":"2015","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejmech.2019.06.092_bib5","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1016\/j.febslet.2012.07.058","article-title":"Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center","volume":"586","author":"Freund","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2019.06.092_bib6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.bmcl.2009.03.007","article-title":"Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis","volume":"19","author":"Akama","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejmech.2019.06.092_bib8","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1021\/acs.jmedchem.8b01719","article-title":"Design of N-benzoxaborole benzofuran GSK8175\u2014optimization of human pharmacokinetics inspired by metabolites of a failed clinical HCV inhibitor","volume":"62","author":"Chong","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib9","doi-asserted-by":"crossref","first-page":"e1151","DOI":"10.1371\/journal.pntd.0001151","article-title":"SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human african trypanosomiasis","volume":"5","author":"Jacobs","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2019.06.092_bib10","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.jorganchem.2009.07.022","article-title":"Benzoxaboroles \u2013 old compounds with new applications","volume":"694","author":"Adamczyk-Wozniak","year":"2009","journal-title":"J.\u00a0Organomet. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib11","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrev.8b00561","article-title":"Metallomimetic chemistry of boron","author":"L\u00e9gar\u00e9","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.06.092_bib12","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s11426-013-4981-y","article-title":"The synthesis of benzoxaboroles and their applications in medicinal chemistry","volume":"56","author":"Zhang","year":"2013","journal-title":"Sci. China Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib13","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1021\/cr500642d","article-title":"Recent developments in the chemistry and biological applications of benzoxaboroles","volume":"115","author":"Adamczyk-Wo\u017aniak","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.06.092_bib14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/med.10043","article-title":"Boronic acid compounds as potential pharmaceutical agents","volume":"23","author":"Yang","year":"2003","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2019.06.092_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00045391-200109000-00005","article-title":"Boron therapeutics on the horizon","volume":"8","author":"Groziak","year":"2001","journal-title":"Am. J. Therapeut."},{"key":"10.1016\/j.ejmech.2019.06.092_bib16","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.1021\/acs.jmedchem.5b01932","article-title":"Challenges and opportunities for the application of boron clusters in drug design","volume":"59","author":"Le\u015bnikowski","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/17460441.2016.1174687","article-title":"Recent developments with boron as a platform for novel drug design","volume":"11","author":"Le\u015bnikowski","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.06.092_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1937-6448(08)00602-3","article-title":"Role of proteasomes in cellular regulation","volume":"267","author":"Konstantinova","year":"2008","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2019.06.092_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2183\/pjab.85.12","article-title":"The proteasome: overview of structure and functions","volume":"85","author":"Tanaka","year":"2009","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.ejmech.2019.06.092_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2019.06.092_bib21","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1073\/pnas.96.20.10976","article-title":"The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study","volume":"96","author":"Groll","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2019.06.092_bib22","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/cmdc.201402075","article-title":"Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents","volume":"9","author":"Scarbaci","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.06.092_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2014.06.017","article-title":"Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors","volume":"83","author":"Troiano","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejmech.2017.01.034","article-title":"Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors","volume":"128","author":"Ge","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.bmc.2018.01.017","article-title":"Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors","volume":"26","author":"Liu","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib26","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.bmcl.2016.03.007","article-title":"Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from \u03b1\u03b1- and \u03b1\u03b2-amino acids","volume":"26","author":"Shi","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib27","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/j.bmc.2016.04.025","article-title":"3D-QSAR-aided design, synthesis, in\u00a0vitro and in\u00a0vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies","volume":"24","author":"Lei","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib28","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.bmc.2018.06.020","article-title":"Design, synthesis, in\u00a0vitro and in\u00a0vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism stud","volume":"26","author":"Lei","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib29","first-page":"4031","article-title":"Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors, Bioorg","volume":"25","author":"Han","year":"2017","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib30","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/j.bmcl.2018.06.004","article-title":"Synthesis and biological evaluation of curcumin derivatives modified with \u03b1-amino boronic acid as proteasome inhibitors","volume":"28","author":"Zhang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ejmech.2016.10.023","article-title":"Urea-containing peptide boronic acids as potent proteasome inhibitors","volume":"125","author":"Han","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib32","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1021\/acs.jmedchem.6b00753","article-title":"Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD)","volume":"59","author":"Liu","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib33","doi-asserted-by":"crossref","first-page":"A17","DOI":"10.1016\/S0149-2918(02)85032-9","article-title":"Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer","volume":"24","author":"Robertson","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2019.06.092_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejmech.2016.03.063","article-title":"10-Boronic acid substituted camptothecin as prodrug of SN-38","volume":"116","author":"Wang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cmdc.201800206","article-title":"Synthesis and evaluation of anticancer and trypanocidal activities of boronic tyrphostins","volume":"13","author":"Hiller","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.06.092_bib36","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bmc.2007.10.075","article-title":"Structure-based optimization of cephalothin-analogue boronic acids as \u03b2-lactamase inhibitors","volume":"16","author":"Morandi","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib37","first-page":"423","article-title":"Beta-lactamase inhibitors. The inhibition of serine beta-lactamases by specific boronic acids","volume":"251","author":"Crompton","year":"1988","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2019.06.092_bib38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11318430-000000000-00000","article-title":"Current challenges in antimicrobial chemotherapy: focus on beta-lactamase inhibition","volume":"70","author":"Bebrone","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2019.06.092_bib39","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1021\/jm5006572","article-title":"Targeting class A and C serine \u03b2-lactamases with a broad-spectrum boronic acid derivative","volume":"57","author":"Tondi","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib40","doi-asserted-by":"crossref","first-page":"17716","DOI":"10.1038\/s41598-017-17399-7","article-title":"Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-\u00e2-lactamases","volume":"7","author":"Santucci","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.06.092_bib41","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1021\/acs.jmedchem.5b00341","article-title":"Click chemistry in lead optimization of boronic acids as \u03b2-lactamase inhibitors","volume":"58","author":"Caselli","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib42","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1128\/AAC.02641-15","article-title":"Boronic acid transition state inhibitors active against KPC and other class A_\u03b2-lactamases: structure-activity relationships as a guide to inhibitor design","volume":"60","author":"Rojas","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.06.092_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1021\/acsinfecdis.7b00152","article-title":"Structure-based analysis of boronic acids as inhibitors of acinetobacter-derived cephalosporinase-7, a unique class C \u03b2-lactamase","volume":"4","author":"Bouza","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.06.092_bib44","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/j.bmc.2018.04.055","article-title":"Boronic acid inhibitors of the class A \u03b2-lactamase KPC-2","volume":"26","author":"Zhou","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2015.02.056","article-title":"Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives","volume":"95","author":"Fontaine","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijantimicag.2012.04.014","article-title":"Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus","volume":"40","author":"Kosmidis","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2019.06.092_bib47","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.bmcl.2017.03.070","article-title":"Novel boronic acid derivatives of bis(indolyl) methane as anti-MRSA agents","volume":"27","author":"Mandal","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib48","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1021\/jm400317w","article-title":"Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase","volume":"57","author":"Maynard","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib49","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1021\/acs.jmedchem.6b01021","article-title":"Peptide\u2212boronic acid inhibitors of flaviviral proteases: medicinal chemistry and structural biology","volume":"60","author":"Nitsche","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib50","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1021\/acs.jmedchem.6b00326","article-title":"Boronic acid modifications enhance the anti-Influenza A virus activities of vovel quindoline derivatives","volume":"60","author":"Wang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.canlet.2008.04.050","article-title":"The role of CXC chemokines and their receptors in cancer","volume":"267","author":"Vandercappellen","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2019.06.092_bib52","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1021\/jm500827t","article-title":"Discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517): noncompetitive boronic acid antagonist of CXCR1 and CXCR2","volume":"57","author":"Maeda","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib53","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.bmcl.2015.04.041","article-title":"Boronic acid-containing CXCR1\/2 antagonists: optimization of metabolic stability, in\u00a0vivo evaluation, and a proposed receptor binding model","volume":"25","author":"Maeda","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib54","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.bmcl.2015.07.090","article-title":"Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1\/2 antagonists: optimization of aqueous solubility and oral bioavailability","volume":"25","author":"Schuler","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib55","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1021\/acs.jmedchem.7b00952","article-title":"Stilbene boronic acids form a covalent bond with human transthyretin and inhibit its aggregation","volume":"60","author":"Smith","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd3620","article-title":"The pharmacological landscape and therapeutic potential of serine hydrolases","volume":"11","author":"Bachovchin","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.06.092_bib57","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1016\/j.bmc.2016.06.022","article-title":"Identification of a novel boronic acid as a potent, selective, and orally active hormone sensitive lipase inhibitor","volume":"24","author":"Ogiyama","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib58","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bmcl.2016.01.071","article-title":"Arylboronic acids as dual-action FAAH and TRPV1 ligands","volume":"26","author":"Morera","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib59","first-page":"507","article-title":"Arylboronic acids. III. Bromination of tolylboronic acids according to Wohl-Ziegler","volume":"10","author":"Torssell","year":"1957","journal-title":"Ark. Kemi."},{"key":"10.1016\/j.ejmech.2019.06.092_bib60","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/MMBR.64.1.202-236.2000","article-title":"Aminoacyl-tRNA Synthetases, the genetic code, and the evolutionary process","volume":"64","author":"Woese","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ejmech.2019.06.092_bib61","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1128\/AAC.01339-16","article-title":"Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.06.092_bib62","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a potent and specific M. tuberculosis leucyl-tRNA synthetase inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib63","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1128\/AAC.00873-16","article-title":"Cryptosporidium and toxoplasma parasites are inhibited by a benzoxaborole targeting leucyl-tRNA synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.06.092_bib64","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1128\/AAC.00820-16","article-title":"Antimalarial benzoxaboroles target Plasmodium falciparum leucyl-tRNA synthetase","volume":"60","author":"Sonoiki","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.06.092_bib65","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1517\/14728222.2015.1067685","article-title":"Bacterial, fungal and protozoan carbonic anhydrases as drug targets","volume":"19","author":"Capasso","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2019.06.092_bib66","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.06.092_bib67","doi-asserted-by":"crossref","first-page":"11983","DOI":"10.1039\/C6CC06399C","article-title":"Benzoxaborole as a new chemotype for carbonic anhydrase inhibition","volume":"52","author":"Alterio","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2019.06.092_bib68","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1021\/acsmedchemlett.7b00369","article-title":"Benzoxaboroles as efficient inhibitors of the \u03b2-carbonic anhydrases from pathogenic fungi: activity and modeling study","volume":"8","author":"Nocentini","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.06.092_bib69","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/14756366.2017.1414808","article-title":"Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles","volume":"33","author":"Nocentini","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib70","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.tet.2016.03.038","article-title":"Synthesis and evaluation of functionalized benzoboroxoles as potential anti-tuberculosis agents","volume":"72","author":"Alam","year":"2016","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2019.06.092_bib71","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tube.2017.11.003","article-title":"The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis","volume":"108","author":"Korkegian","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2019.06.092_bib72","doi-asserted-by":"crossref","first-page":"14574","DOI":"10.1038\/ncomms14574","article-title":"A\u00a0potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue","volume":"8","author":"Sonoiki","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2019.06.092_bib73","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1021\/acs.jmedchem.5b00678","article-title":"Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles","volume":"58","author":"Zhang","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib74","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1021\/acs.jmedchem.7b00621","article-title":"Benzoxaborole antimalarial agents. Part 5. Lead optimization of novel amide pyrazinyloxy benzoxaboroles and identification of a preclinical candidate","volume":"60","author":"Zhang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib75","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3390\/molecules23082038","article-title":"Cinnamoyl-oxaborole amides: synthesis and their in\u00a0vitro biological activity","volume":"23","author":"Gumbo","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2019.06.092_bib76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejmech.2014.04.079","article-title":"Novel pyrrolobenzoxaboroles: design, synthesis, and biological evaluation against Trypanosoma brucei","volume":"81","author":"Wu","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bmcl.2017.11.028","article-title":"Identification of a 4-fluorobenzyl L-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT)","volume":"28","author":"Akama","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib78","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1016\/j.bmcl.2015.10.044","article-title":"Discovery of an orally bioavailable isoxazoline benzoxaborole (AN8030) as a long acting animal ectoparasiticide","volume":"25","author":"Zhang","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib79","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.bmcl.2016.04.093","article-title":"Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide","volume":"26","author":"Zhang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02419-17","article-title":"Topical treatment for cutaneous Leishmaniasis: dermato-pharmacokinetic lead optimization of benzoxaboroles","volume":"62","author":"Van Bocxlaer","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2019.06.092_bib81","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/acs.jmedchem.8b01854","article-title":"Boron-pleuromutilins as anti-Wolbachia agents with potential for treatment of onchocerciasis and lymphatic filariasis","volume":"62","author":"Jacobs","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib82","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1021\/acsinfecdis.5b00031","article-title":"4,5-Disubstituted 6-Aryloxy-1,3-dihydrobenzo[c][1,2]oxaboroles are broad-spectrum serine \u03b2-lactamase inhibitors","volume":"1","author":"McKinney","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2019.06.092_bib83","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41429-018-0107-2","article-title":"Synthesis and evaluation of biological activity of benzoxaborole derivatives of azithromycin","volume":"72","author":"Tevyashova","year":"2019","journal-title":"J.\u00a0Antibiot. (Tokyo)"},{"key":"10.1016\/j.ejmech.2019.06.092_bib84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10637-018-0611-z","article-title":"Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology \u2013 phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells","volume":"37","author":"Psurski","year":"2019","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ejmech.2019.06.092_bib85","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1016\/j.bmcl.2018.10.032","article-title":"A\u00a0hit deconstruction approach for the discovery of fetal hemoglobin inducers","volume":"28","author":"Benowitz","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib86","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.116.232819","article-title":"Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes","volume":"358","author":"Dong","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2019.06.092_bib87","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1039\/C8MD00315G","article-title":"Discovery of boron-containing compounds as A\u03b2 aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease","volume":"8","author":"Lu","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2019.06.092_bib88","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1021\/jm500045x","article-title":"Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates","volume":"57","author":"Kawamura","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib89","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.ejmech.2018.08.086","article-title":"Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting Escherichia coli type I signal peptidase","volume":"157","author":"Sza\u0142aj","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.092_bib90","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.bmcl.2014.05.056","article-title":"Pentapeptide boronic acid inhibitors of Mycobacterium tuberculosis MycP1 protease","volume":"24","author":"Frasinyuk","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.092_bib91","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1021\/acsomega.8b00702","article-title":"Diazaborines as new inhibitors of human neutrophil elastase","volume":"3","author":"Ant\u00f3nio","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2019.06.092_bib92","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1107\/S2053230X15022098","article-title":"Crystallographic insights into the structure\u2013activity relationships of diazaborine enoyl-ACP reductase inhibitors","volume":"71","author":"Jordan","year":"2015","journal-title":"Acta Crystallogr. F Struct. Biol. Commun."},{"key":"10.1016\/j.ejmech.2019.06.092_bib93","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-immunol-030409-101311","article-title":"The sterile inflammatory response","volume":"28","author":"Rock","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2019.06.092_bib94","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/cmdc.201700731","article-title":"Design, synthesis and evaluation of novel oxazaborine inhibitors of the NLRP3 inflammasome","volume":"13","author":"Baldwin","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.06.092_bib95","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.chembiol.2017.08.011","article-title":"Boron-based inhibitors of the NLRP3 inflammasome","volume":"24","author":"Baldwin","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.06.092_bib96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cbi.2013.12.011","article-title":"Antiproliferative activity and therapeutic implications of potassium tris(4-methyl-1-pyrazolyl) borohydride in hepatocellular carcinoma","volume":"213","author":"Jin","year":"2014","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2019.06.092_bib97","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1039\/C8OB02668H","article-title":"Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer","volume":"17","author":"Lei","year":"2019","journal-title":"Org. Biomol. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419306191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419306191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:04:25Z","timestamp":1759327465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419306191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":97,"alternative-id":["S0223523419306191"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.092","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Boron in drug design: Recent advances in the development of new therapeutic agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}